Weizmann Science Park
16 Einstein St. P.O.Box 4113
11 articles with Mapi Pharma
Patient recruitment in Phase III trial has surpassed 60% Trial is expanded to Israel with first clinical site at Tel Aviv Medical Center
Mapi Pharma Announces Commissioning of a Vaccine Production Facility to Support the Supply of COVID-19 Vaccines to Israel and EU Countries
Facility in the Jerusalem Har-Hotzim technology park is built at the highest GMP standards; capability to provide reliable supply of COVID-19 vaccines, if approved
Mapi Pharma Presents Glatiramer Acetate Depot (GA Depot) Results at the 8th Joint ACTRIMS-ECTRIMS Meeting MSVirtual2020
Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company, today announced that it will present data from its ongoing Phase II studies of GA Depot for the treatment of relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) at MS Virtual 2020,
First Patient Treated in Mapi Pharma’s Phase II Clinical Trial of GA Depot for Primary Progressive Multiple Sclerosis (PPMS)
This is a Phase II prospective, multicenter, single arm, open label study designed to assess the safety and efficacy of GA Depot in delaying the accumulation of disability in subjects with PPMS.
Mapi Pharma Announces Presentation of Phase II Results of Glatiramer Acetate Depot at ECTRIMS-ACTRIMS 2017 Congress in Paris
A total of 25 subjects previously treated for at least one year with Copaxone were enrolled.
First Patient Treated In Mapi Pharma's Phase 2a Clinical Trial Of GA Depot For Relapsing Remitting Multiple Sclerosis (RRMS)
Mapi Pharma Granted United States Patent Covering The Process For The Preparation Of Fingolimod For Multiple Sclerosis